(Q34371493)

1 August 2017

Toxicity and efficacy of concurrent gemcitabine and radiotherapy for locally advanced pancreatic cancer (English)

1 reference

1 August 2017

0 references

1 reference

C H Crane

1

1 reference

1 August 2017

N A Janjan

2

1 reference

1 August 2017

D B Evans

3

1 reference

1 August 2017

R A Wolff

4

1 reference

1 August 2017

M T Ballo

5

1 reference

1 August 2017

L Milas

6

1 reference

1 August 2017

K Mason

7

1 reference

1 August 2017

C Charnsangavej

8

1 reference

1 August 2017

P W Pisters

9

1 reference

1 August 2017

J E Lee

10

1 reference

1 August 2017

R Lenzi

11

1 reference

1 August 2017

J N Vauthey

12

1 reference

1 August 2017

A Wong

13

1 reference

1 August 2017

T Phan

14

1 reference

1 August 2017

Q Nguyen

15

1 reference

1 August 2017

J L Abbruzzese

16

1 reference

1 August 2017

1 January 2001

1 reference

International Journal of Pancreatology

1 August 2017

1 reference

1 August 2017

29

1 reference

1 August 2017

1

1 reference

1 August 2017

9-18

1 reference

Enhancement of tumor radioresponse in vivo by gemcitabine

1 August 2017

1 reference

12 December 2020

Gemcitabine-mediated radiosensitization.

1 reference

12 December 2020

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine

1 reference

12 December 2020

Combined intraoperative radiation and perioperative chemotherapy for unresectable cancers of the pancreas

1 reference

12 December 2020

Phase I trial of gemcitabine combined with radiation for the treatment of locally advanced pancreatic adenocarcinoma.

1 reference

12 December 2020

Intraoperative and external beam irradiation +/- 5-FU for locally advanced pancreatic cancer

1 reference

12 December 2020

Intraoperative radiation therapy for patients with pancreatic carcinoma

1 reference

12 December 2020

Maximizing therapeutic gain with gemcitabine and fractionated radiation

1 reference

12 December 2020

Phase I trial of twice-weekly gemcitabine and concurrent radiation in patients with advanced pancreatic cancer

1 reference

12 December 2020

A multi-institutional comparative trial of radiation therapy alone and in combination with 5-fluorouracil for locally unresectable pancreatic carcinoma. The Gastrointestinal Tumor Study Group

1 reference

12 December 2020

Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas

1 reference

12 December 2020

Combined 5-fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer

1 reference

12 December 2020

Radiation therapy combined with Adriamycin or 5-fluorouracil for the treatment of locally unresectable pancreatic carcinoma. Gastrointestinal Tumor Study Group

1 reference

12 December 2020

Long-term results of combined modality treatment with I-125 implantation for carcinoma of the pancreas

1 reference

12 December 2020

Enhancement of radiation-induced regrowth delay by gemcitabine in a human tumor xenograft model

1 reference

12 December 2020

Combined modality treatment of localized unresectable adenocarcinoma of the pancreas

1 reference

12 December 2020

Radiosensitization produced in vivo by once- vs. twice-weekly 2'2'-difluoro-2'-deoxycytidine (gemcitabine)

1 reference

12 December 2020

High-dose preoperative external beam and intraoperative irradiation for locally advanced pancreatic cancer

1 reference

12 December 2020

Treatment of locally unresectable carcinoma of the pancreas: comparison of combined-modality therapy (chemotherapy plus radiotherapy) to chemotherapy alone. Gastrointestinal Tumor Study Group

1 reference

12 December 2020

External beam versus intraoperative and external beam irradiation for locally advanced pancreatic cancer

1 reference

12 December 2020

Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6000 rads) radiation alone, moderate dose radiation (4000 rads + 5-fluorouracil), and high dose radiation + 5-fluorouracil: The Gastrointestinal Tumor Study

1 reference

12 December 2020

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

12 December 2020

Identifiers

DOI

10.1385/IJGC:29:1:09

1 reference

1 August 2017

1 reference